At a glance
ClinicalIndex Comparison RecordN/ACompleted· 181 enrolled
Drug / intervention
therapy regimenbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of iPro™2 in Real Life Diabetes Management of Type 2 Patients in India
In Brief
A clinical study evaluating therapy regimen for Diabetes Mellitus, Type 2. Completed, enrolled 181 participants across 11 sites.
Detailed Summary
The purpose of the India iPro2 study is to demonstrate that iPro2 Continuous Glucose Monitoring System (CGMS) evaluation enables Health Care Professional (HCP)s treating patients in India with type 2 diabetes to get a better understanding of their patient's metabolic fluctuations, and support appropriate therapeutic intervention.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesIndia
CollaboratorsMedtronic
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedNov 2013
Primary CompletionJan 2014
Study CompletionApr 2014
TodayJul 2026
First PostedNov 26, 2013
Enrollment StartDec 1, 2012
Primary CompletionJan 1, 2014
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.6 years ago
Interventions
therapy regimenbehavioral
Subjects will be recommend changes in therapy regimens.